Editorial · 2021 · Open access
The “Coming of Age” of Real‐World Evidence in Drug Development and Regulation
Clinical Pharmacology & Therapeutics, 111(1), 11–14 · Published 16 December 2021 · DOI 10.1002/cpt.2465
In brief
“The “Coming of Age” of Real‐World Evidence in Drug Development and Regulation” is an 2021 editorial by Peter K. Honig, published in Clinical Pharmacology & Therapeutics. OpenAlex counts 10 citations as of 22 November 2026. It is open access: the full text is free to read at Clinical Pharmacology & Therapeutics.
- Citations
- 10
- Most cited in
- 2023 (4)
- References
- 18
- Authors
- 1
Abstract
Real world evidence (RWE) has the potential to inform drug discovery, development, and regulatory decision making. The emergence and availability of large population-based datasets around the globe have stoked enthusiasm in the research community. However, much work remains to refine research methodologies, evolve the science, and define the place of RWE as a complementary source of evidence to randomized controlled trials.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Honig, P. K. (2021). The “Coming of Age” of Real‐World Evidence in Drug Development and Regulation. Clinical Pharmacology & Therapeutics, 111(1), 11–14. https://doi.org/10.1002/cpt.2465
MLA 9
Honig, Peter K. “The “Coming of Age” of Real‐World Evidence in Drug Development and Regulation.” Clinical Pharmacology & Therapeutics, vol. 111, no. 1, 2021, pp. 11–14. https://doi.org/10.1002/cpt.2465.
Chicago
Honig, Peter K. 2021. “The “Coming of Age” of Real‐World Evidence in Drug Development and Regulation.” Clinical Pharmacology & Therapeutics 111 (1): 11–14. https://doi.org/10.1002/cpt.2465.
Harvard
Honig, P. K. (2021) ‘The “Coming of Age” of Real‐World Evidence in Drug Development and Regulation’, Clinical Pharmacology & Therapeutics, 111(1), pp. 11–14. doi:10.1002/cpt.2465.
IEEE
P. K. Honig, “The “Coming of Age” of Real‐World Evidence in Drug Development and Regulation,” Clinical Pharmacology & Therapeutics, vol. 111, no. 1, pp. 11–14, 2021, doi: 10.1002/cpt.2465.
BibTeX
@article{honig2021coming,
title = {{The “Coming of Age” of Real‐World Evidence in Drug Development and Regulation}},
author = {Honig, Peter K.},
journal = {Clinical Pharmacology \& Therapeutics},
year = {2021},
volume = {111},
number = {1},
pages = {11--14},
doi = {10.1002/cpt.2465},
url = {https://doi.org/10.1002/cpt.2465}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2022 | 1 | |
| 2023 | 4 | |
| 2024 | 2 | |
| 2025 | 2 | |
| 2026 | 1 |
Topic and keywords
Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- real-world evidence
- drug development
- drug regulation
- randomized controlled trials
- evidence-based decision making
- drug discovery
Work with this paper
Most-cited papers in Economics, Econometrics and Finance
- Theory of the firm: Managerial behavior, agency costs and ownership structureMichael C. Jensen, William H. Meckling · Journal of Financial Economics · 1976 · 77,585 citations
- Institutions, Institutional Change and Economic PerformanceDouglass C. North · Cambridge University Press eBooks · 1990 · 34,377 citations
- The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.John E. Ware, Cathy Donald Sherbourne · PubMed · 1992 · 33,943 citations
- Some Tests of Specification for Panel Data: Monte Carlo Evidence and an Application to Employment EquationsManuel Arellano, Stephen R. Bond · The Review of Economic Studies · 1991 · 33,778 citations
- Co-Integration and Error Correction: Representation, Estimation, and TestingRobert F. Engle, C.W.J. Granger · Econometrica · 1987 · 32,847 citations
Questions about this paper
How do I cite this paper in APA style?
Honig, P. K. (2021). The “Coming of Age” of Real‐World Evidence in Drug Development and Regulation. Clinical Pharmacology & Therapeutics, 111(1), 11–14. https://doi.org/10.1002/cpt.2465
How many times has this paper been cited?
10 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Clinical Pharmacology & Therapeutics: sign in and open the PDF from this page.
Who wrote this paper?
Peter K. Honig.
What is the DOI of this paper?
10.1002/cpt.2465, permanently at https://doi.org/10.1002/cpt.2465. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.